Showing results (711-720 of 1,340) with videos related to

Sort By:
Pageof 134
Neuro-Oncology Advances|February 14, 2022
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot studyNir Peled, Waleed Kian, Edna Inbar, et al.
Neuro-Oncology Advances|October 27, 2021
Multimodal therapy of cavernous sinus meningioma: Impact of surgery and 68Ga-DOTATATE PET-guided radiation therapy on tumor control and functional outcomeIndrawati Hadi, Annamaria Biczok, Nicole Terpolilli, et al.
Neuro-Oncology Advances|October 27, 2021
ELTD1 as a multi-focal target for malignant gliomas: preclinical studiesMichelle Zalles, Nataliya Smith, Debra Saunders, et al.
Neuro-Oncology Advances|October 25, 2021
Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastomaShiao-Pei Weathers, Julie Rood-Breithaupt, John de Groot, et al.
Neuro-Oncology Advances|October 1, 2021
Transitioning to molecular diagnostics in pediatric high-grade glioma: experiences with the 2016 WHO classification of CNS tumorsJoshua N Baugh, Gerrit H Gielen, Dannis G van Vuurden, et al.
Neuro-Oncology Advances|July 25, 2022
Nicotinamide riboside alleviates cisplatin-induced peripheral neuropathy via SIRT2 activationScarlett Acklin, Ratan Sadhukhan, Wuying Du, et al.
Neuro-Oncology Advances|July 25, 2022
Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinibYeshavanth Kumar Banasavadi-Siddegowda, Sriya Namagiri, Yoshihiro Otani, et al.
Neuro-Oncology Advances|April 11, 2022
Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143Antonio Omuro, David A Reardon, John H Sampson, et al.
Neuro-Oncology Advances|April 27, 2022
Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastomaSonja Krausert, Sebastian Brabetz, Norman L Mack, et al.
Neuro-Oncology Advances|April 27, 2022
Temporal muscle thickness as an independent prognostic imaging marker in newly diagnosed glioblastoma patients: A validation studyMartinus P G Broen, Rueben Beckers, Anna C H Willemsen, et al.
Pageof 134